"Drug makers see new wave in multiple sclerosis care" by Rob Waters, Bloomberg News | April 28, 2009
SAN FRANCISCO - The first in a new wave of multiple sclerosis medicines, from drug makers led by Novartis AG and Merck KGaA, may reach the market next year, making therapy more convenient for patients and boosting profits....
There is your problem with AmeriKa's sick-making "health care" system.
Three new drugs were approved to prevent MS relapses. They included two made from proteins called beta interferons - Avonex, made by Biogen Idec Inc. of Cambridge, Mass., and Betaferon, made by Bayer AG of Levrkusen, Germany. The third treatment is Copaxone, made by Teva Pharmaceutical Industries Ltd., of Petah Tikva, Israel, from a synthetic protein.
Related: Biogen Benefits From Brain Disease
The Money Pipeline From Massachusetts to Israel
The newest MS treatment on the market, Biogen's Tysabri, blocks the movement of immune cells from the bloodstream into the nervous system.
And also gives the patient brain disease.
--more--"
